Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease.

@article{Aylward2007ChangeIM,
  title={Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease.},
  author={Elizabeth H. Aylward},
  journal={Brain research bulletin},
  year={2007},
  volume={72 2-3},
  pages={152-8}
}
This article discusses the need for biomarkers and surrogate endpoints for future clinical trials in individuals at risk for Huntington's disease. Definitions and criteria are presented for biomarkers and surrogate endpoints, and data are presented suggesting that striatal volumes, as measured on MRI scans, meet the criteria for a biomarker. Biomarkers can be used in lieu of clinical endpoints in treatment trials if there is evidence that treatment affects the biomarker in a way that is… CONTINUE READING

From This Paper

Topics from this paper.
46 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

Similar Papers

Loading similar papers…